SCHEMBL18237347

SCHEMBL18237347

CC(C)C(=O)NCCC[Si](C)(C)O[Si](C)(C)CCc1ncccn1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP2D6 P10635 2/20 0.46
KMT2A Q03164 2/20 0.46
MTNR1A P48039 8/20 0.44
MTNR1B P49286 7/20 0.44
RECQL P46063 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 2/20 0.36
ATM Q13315 1/20 0.36
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
NQO2 P16083 1/20 0.34
BRD4 O60885 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18227216 0.83 KMT2A (0.45) CYP2C9CYP2C19CYP2D6KMT2AMTNR1A
SCHEMBL18237464 0.82 MTNR1A (0.41) CYP2C9CYP2C19CYP2D6KMT2AMTNR1A
SCHEMBL18237352 0.81 KMT2A (0.40) CYP2C9CYP2C19CYP2D6KMT2AMTNR1A
SCHEMBL18238491 0.78 CYP2C19 (0.39) CYP2C9CYP2C19CYP2D6KMT2AMTNR1A
SCHEMBL18237605 0.78 CYP2C19 (0.39) CYP2C9CYP2C19CYP2D6KMT2AMTNR1A
SCHEMBL18227240 0.76 KMT2A (0.40) CYP2C9CYP2C19CYP2D6KMT2AMTNR1A
SCHEMBL13819943 0.70 ERCC1 (0.45) CYP2C9CYP2C19CYP2D6KMT2ARECQL
SCHEMBL13171211 0.67 KMT2A (0.42) CYP2C9CYP2C19CYP2D6KMT2AMTNR1A
SCHEMBL20964586 0.66 ALDH1A1 (0.55) CYP2C9CYP2C19CYP2D6KMT2AMTNR1A
SCHEMBL18237463 0.66 KMT2A (0.47) CYP2C9CYP2C19CYP2D6KMT2AMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000993-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO INC (US) 2023-01-05 US disclosed
US-20230000993-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO INC (US) 2023-01-05 US disclosed
US-11291731-B2 Silicon based drug conjugates and methods of using same BLINKBIO, INC. (US) 2022-04-05 US disclosed
US-20190290771-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO, INC. 2019-09-26 US disclosed
US-20190290771-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO, INC. 2019-09-26 US disclosed
US-9931407-B2 Silicon based drug conjugates and methods of using same BLINKBIO, INC. (US) 2018-04-03 US disclosed
US-20170202970-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO, INC. 2017-07-20 US disclosed
WO-2016183359-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO, INC. (US) 2016-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170202970-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME CD44, MSN, AS3MT CYP2C9 3104/4885CYP2C19 3490/4885CYP2D6 2628/4885
US-11291731-B2 Silicon based drug conjugates and methods of using same CD44, MSN, AS3MT CYP2C9 3104/4885CYP2C19 3490/4885CYP2D6 2628/4885
US-20190290771-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME CD44, MSN, AS3MT CYP2C9 3104/4885CYP2C19 3490/4885CYP2D6 2628/4885
US-20230000993-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME CD44, MSN, AS3MT CYP2C9 3104/4885CYP2C19 3490/4885CYP2D6 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.